Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea
Purpose Few studies have investigated the impact of biologics on the risk of major adverse cardiovascular events (MACEs) among Korean patients with psoriatic diseases. We compared the risk of MACEs and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor (TNF)...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2321194 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064131374186496 |
|---|---|
| author | Hyesoo Cho Ye-Jee Kim Ik Jun Moon Woo Jin Lee Chong Hyun Won Mi Woo Lee Sung Eun Chang Joon Min Jung |
| author_facet | Hyesoo Cho Ye-Jee Kim Ik Jun Moon Woo Jin Lee Chong Hyun Won Mi Woo Lee Sung Eun Chang Joon Min Jung |
| author_sort | Hyesoo Cho |
| collection | DOAJ |
| description | Purpose Few studies have investigated the impact of biologics on the risk of major adverse cardiovascular events (MACEs) among Korean patients with psoriatic diseases. We compared the risk of MACEs and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor (TNF)-α and interleukin (IL)-12/23 inhibitors in Korea.Methods Patients with psoriatic disease prescribed with TNF-α and IL-12/23 inhibitors since 2016 were selected from the Korean National Health Insurance Service (NHIS) Database. Follow-up data for MACEs and all-cause mortality between 2016 and 2020 were collected. A total of 2886 individuals were included, including 1987 IL-12/23 inhibitor users and 899 TNF-α inhibitor users.Results Compared with IL-12/23 inhibitor users, TNF-α inhibitor users had a higher prevalence of dyslipidemia and a significantly higher risk of all-cause mortality but not MACE. After controlling for age, female TNF-α inhibitor users had a significantly increased risk of all-cause mortality. Meanwhile, after controlling for sex, TNF-α inhibitor users aged 60 years or older demonstrated a significantly elevated risk of all-cause mortality. In conclusion, No statistically significant difference in MACE risk was observed between patients who used TNF-α and IL-12/23 inhibitors. Nevertheless, the use of IL-12/23 inhibitors, especially among older and female patients, resulted in a lower overall mortality. |
| format | Article |
| id | doaj-art-ce10aff95b9e46b7970e9436cd202dfb |
| institution | DOAJ |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-ce10aff95b9e46b7970e9436cd202dfb2025-08-20T02:49:23ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2321194Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in KoreaHyesoo Cho0Ye-Jee Kim1Ik Jun Moon2Woo Jin Lee3Chong Hyun Won4Mi Woo Lee5Sung Eun Chang6Joon Min Jung7Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaPurpose Few studies have investigated the impact of biologics on the risk of major adverse cardiovascular events (MACEs) among Korean patients with psoriatic diseases. We compared the risk of MACEs and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor (TNF)-α and interleukin (IL)-12/23 inhibitors in Korea.Methods Patients with psoriatic disease prescribed with TNF-α and IL-12/23 inhibitors since 2016 were selected from the Korean National Health Insurance Service (NHIS) Database. Follow-up data for MACEs and all-cause mortality between 2016 and 2020 were collected. A total of 2886 individuals were included, including 1987 IL-12/23 inhibitor users and 899 TNF-α inhibitor users.Results Compared with IL-12/23 inhibitor users, TNF-α inhibitor users had a higher prevalence of dyslipidemia and a significantly higher risk of all-cause mortality but not MACE. After controlling for age, female TNF-α inhibitor users had a significantly increased risk of all-cause mortality. Meanwhile, after controlling for sex, TNF-α inhibitor users aged 60 years or older demonstrated a significantly elevated risk of all-cause mortality. In conclusion, No statistically significant difference in MACE risk was observed between patients who used TNF-α and IL-12/23 inhibitors. Nevertheless, the use of IL-12/23 inhibitors, especially among older and female patients, resulted in a lower overall mortality.https://www.tandfonline.com/doi/10.1080/09546634.2024.2321194Arthritisinterleukin inhibitorsheart disease risk factorspsoriasisRepublic of Koreatumor necrosis factor inhibitors |
| spellingShingle | Hyesoo Cho Ye-Jee Kim Ik Jun Moon Woo Jin Lee Chong Hyun Won Mi Woo Lee Sung Eun Chang Joon Min Jung Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea Journal of Dermatological Treatment Arthritis interleukin inhibitors heart disease risk factors psoriasis Republic of Korea tumor necrosis factor inhibitors |
| title | Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea |
| title_full | Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea |
| title_fullStr | Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea |
| title_full_unstemmed | Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea |
| title_short | Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea |
| title_sort | risk of major adverse cardiovascular events and all cause mortality among patients with psoriatic disease treated with tumor necrosis factor α and interleukin 12 23 inhibitors a nationwide population based cohort study in korea |
| topic | Arthritis interleukin inhibitors heart disease risk factors psoriasis Republic of Korea tumor necrosis factor inhibitors |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2321194 |
| work_keys_str_mv | AT hyesoocho riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT yejeekim riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT ikjunmoon riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT woojinlee riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT chonghyunwon riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT miwoolee riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT sungeunchang riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea AT joonminjung riskofmajoradversecardiovasculareventsandallcausemortalityamongpatientswithpsoriaticdiseasetreatedwithtumornecrosisfactoraandinterleukin1223inhibitorsanationwidepopulationbasedcohortstudyinkorea |